Wells Fargo Initiates Coverage On Adaptimmune Therapeutics PLC – ADR to Market Perform

Wells Fargo Initiates Coverage On Adaptimmune Therapeutics PLC – ADR(ADAP). The shares have been rated Market Perform. The rating by the stock financial advisor at Wells Fargo was issued on Mar 17, 2017 in a research report to their Investors and Clients.

Adaptimmune Therapeutics PLC – ADR (ADAP) made into the market gainers list on Wednesdays trading session with the shares advancing 0.23% or 0.01 points. Due to strong positive momentum, the stock ended at $4.3, which is also near the day’s high of $4.35. The stock began the session at $4.17 and the volume stood at 21,62,383 shares. The 52-week high of the shares is $11.5881 and the 52 week low is $3.76. The company has a current market capitalization of $304 M and it has 7,07,95,848 shares in outstanding.

Adaptimmune Therapeutics PLC – ADR(ADAP) last announced its earnings results on Mar 13, 2017 for Fiscal Year 2017 and Q2.Company reported revenue of $8.536M. Analysts had an estimated revenue of $3.830M. Earnings per share were $-0.22. Analysts had estimated an EPS of $-0.27.

Several Insider Transactions has been reported to the SEC. On May 25, 2016, Peter A. Thompson (director) purchased 1,712,400 shares at $10.31 per share price.Also, On May 19, 2016, Charles Elliott Sigal (director) purchased 15,000 shares at $1.56 per share price.

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its T-cell receptor platform. The Company has developed a platform that enables to identify cancer targets in the form of peptides which are short sequences of amino acids find and genetically engineer T-cell receptors (TCRs) and produce TCR therapeutic candidates for administration to patients. The Company’s target peptides are NY-ESO-1 and MAGE A-10. The Company’s affinity-enhanced TCR therapeutics targets the NY-ESO-1 or NY-ESO cancer antigen. The Company has completed the Phase I/II clinical trials for its NY-ESO TCR therapeutic candidate in patients with solid tumors and hematological malignancies including synovial sarcoma multiple myeloma melanoma ovarian cancer and esophageal cancer.

Add Comment